This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Denmark
ACE BioSciences A/S is a pharmaceutical company, which discovers and develops novel vaccines for the prevention and treatment of bacterial infections. Company's products include Campylobacter and Enterotoxigenic Escherichia Coli vaccines to prevent Travellers' Diarrhoea; Prevnar vaccine to prevent pneumococcal infections; Gardasil and Cervarix vaccines for the treatment against cervical cancer; Streptococcus Pneumoniae vaccine to prevent infection with Streptococcus Pneumoniae; and ACE820 that targets infections caused by Clostridium diffjicile and Moraxella Catarrhalis
Acesion Pharma is a Danish biotech company which develops more efficacious and safer drugs for the medical treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
Adenium Biotech is a Danish biopharmaceutical, that focuses on the development and commercialization of novel antibiotics for the treatment of multi drug resistant bacterial infections. The company's focus is in the treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria.
Affitech A/S is a biopharmaceutical company focused on developing human antibody therapeutics derived from the Company?s human antibody platform bringing new treatment options to improve patients? lives. The Company is developing a novel anti-VEGF antibody AT001/r84 with a unique specificity that may offer improved anti-angiogenesis therapy.
Aniona is a management buy out from NeuroSearch.
A large portfolio of CNS and ion channel assets have been assigned to Aniona including an active R&D alliance with J&J.
J
A large portfolio of CNS and ion channel assets have been assigned to Aniona including an active R&D alliance with J&J.
J
ARTS Biologics is focusing on developing a range of improved gonadotrophins to facilitate modern assisted reproductive therapy with single embryo transfer and lower side effects.
Astion Pharma specializes in new products for large orphan diseases and autoimmune or inflammatory conditions with dermatological manifestations. Company's lead product ASF-1096 has a unique mechanism of action in dermatology and is conveniently administered topically for the treatment of CLE.
BAVARIAN NORDIC (CSE:BAVA)
with global headquarters in Denmark, is a biopharmaceutical company developing and producing novel (off-the-shelf ) vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need.
Their company focuses on developing product candidates to address cancer and infectious diseases.
with global headquarters in Denmark, is a biopharmaceutical company developing and producing novel (off-the-shelf ) vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need.
Their company focuses on developing product candidates to address cancer and infectious diseases.
BKG Pharma is a privately held biopharmaceutical company focused on the discovery and development of new classes of antimicrobials against multiresistant bacteria. Utilizing its proprietary of the New Classes of Antimicrobials and Drug Discovery and Development capabilities, BKG Pharma maximizes the drug development process.
Borean Pharma is a science-based company aiming to develop its unique proprietory protein technology platform for rapid development of human protein products with new desired ligand binding properties, which may replace or supersede antibody products in pharmaceutical applications.
Conrig Pharma engages in development of drug for oral treatment of atopical dermatitis. Conrig Pharma has initiated several projects for treatment of treatment of dermatological disorders and neuropatic pain. Initial focus will be on development of a new drug (CRG-010) for topical treatment of itch/pruritus associated with atopical dermatitis.